Association Between Disease Severity and Clinical, Histopathological, and Eosinophilic Markers in Patients With Bullous Pemphigoid (BP-EPIC) (BP-EPIC)
Correlation of Disease Severity With Histopathological Features, Serum IgE Levels, Eosinophil Count, and Tissue Expression of Eosinophilic Cationic Protein and Periostin in Patients With Bullous Pemphigoid
Bullous pemphigoid is an autoimmune subepidermal blistering disease characterized by eosinophilic inflammation and variable disease severity. This retrospective observational study aims to evaluate the relationship between disease severity and histopathological features, serum IgE levels, peripheral eosinophil counts, and the expression of eosinophilic cationic protein (ECP) and periostin in skin biopsy specimens of patients with bullous pemphigoid.
Immunohistochemical staining for ECP and periostin will be assessed semi-quantitatively and correlated with clinical and laboratory parameters, including BPDAI scores, eosinophil counts, serum IgE levels, hospitalization history, and disease relapse. The study seeks to identify potential tissue biomarkers associated with disease activity and severity in bullous pemphigoid.
Tutkimuksen yleiskatsaus
Tila
Ehdot
Yksityiskohtainen kuvaus
Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease and is characterized by autoantibodies directed against hemidesmosomal proteins. Eosinophils and eosinophil-associated mediators are believed to play a central role in disease pathogenesis. Periostin and eosinophilic cationic protein (ECP) have been implicated in eosinophilic inflammation; however, their relationship with clinical disease severity in BP remains incompletely understood.
This single-center retrospective observational study will include patients diagnosed with bullous pemphigoid at the University of Health Sciences, Istanbul Training and Research Hospital. Clinical, laboratory, and histopathological data will be collected from medical records.
The study will evaluate demographic characteristics, disease severity measured by BPDAI, serum IgE levels, peripheral eosinophil counts, hospitalization history, relapse frequency, and other clinicopathological parameters. Archived skin biopsy specimens will undergo immunohistochemical staining for periostin and ECP. Staining intensity will be assessed using semi-quantitative scoring methods and correlated with clinical and laboratory findings.
The primary objective is to determine whether periostin and ECP expression levels are associated with disease severity. Secondary objectives include evaluating correlations between tissue biomarker expression and serum IgE levels, eosinophil counts, hospitalization, and disease recurrence.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Yhteystiedot ja paikat
Opiskelupaikat
-
-
FATİH
-
Istanbul, FATİH, Turkki (Türkiye), 34096
- S.B.Ü. İstanbul Eğitim ve Araştırma Hastanesi
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Aikuinen
- Vanhempi Aikuinen
Hyväksyy terveitä vapaaehtoisia
Näytteenottomenetelmä
Tutkimusväestö
Kuvaus
Inclusion Criteria:
- Age ≥18 years.
- Diagnosis of bullous pemphigoid confirmed by compatible clinical, histopathological, and/or direct immunofluorescence findings.
- Availability of archived skin biopsy specimens suitable for immunohistochemical evaluation of periostin and eosinophilic cationic protein (ECP).
- Availability of clinical and laboratory data, including BPDAI score, serum IgE level, and peripheral eosinophil count.
Exclusion Criteria:
- Age <18 years.
- Diagnosis other than bullous pemphigoid.
- Inadequate or unavailable biopsy specimens for immunohistochemical analysis.
- Missing clinical, histopathological, or laboratory data required for study analyses.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
Kohortit ja interventiot
Ryhmä/Kohortti |
|---|
|
Bullous Pemphigoid Patients
Patients with bullous pemphigoid included in a retrospective observational study evaluating the relationship between disease severity and periostin and ECP expression in skin biopsy specimens.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Correlation Between BPDAI Score and Periostin Immunohistochemical Expression
Aikaikkuna: Baseline (retrospective assessment of existing clinical and histopathological data)
|
Correlation between BPDAI disease activity score and periostin immunohistochemical expression measured using a semiquantitative 0-3 staining score in skin biopsy specimens from patients with bullous pemphigoid.
|
Baseline (retrospective assessment of existing clinical and histopathological data)
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Correlation Between Periostin Immunohistochemical Expression and Serum Total IgE Levels
Aikaikkuna: Baseline (retrospective assessment of existing clinical, laboratory, and histopathological data
|
Correlation between periostin immunohistochemical expression measured using a semiquantitative 0-3 staining score in skin biopsy specimens and serum total IgE levels (IU/mL) in patients with bullous pemphigoid.
|
Baseline (retrospective assessment of existing clinical, laboratory, and histopathological data
|
|
Correlation Between Eosinophilic Cationic Protein Immunohistochemical Expression and Peripheral Blood Eosinophil Count
Aikaikkuna: Baseline (retrospective assessment of existing clinical, laboratory, and histopathological data)
|
Correlation between eosinophilic cationic protein (ECP) immunohistochemical expression measured using a semiquantitative 0-3 staining score in skin biopsy specimens and peripheral blood eosinophil count (cells/µL) in patients with bullous pemphigoid.
|
Baseline (retrospective assessment of existing clinical, laboratory, and histopathological data)
|
|
Correlation Between Periostin Expression and Disease Relapse Frequency
Aikaikkuna: Baseline (retrospective assessment of existing clinical and histopathological data
|
Correlation between periostin immunohistochemical expression measured using a semiquantitative 0-3 staining score in skin biopsy specimens and disease relapse frequency (number of relapses) in patients with bullous pemphigoid.
|
Baseline (retrospective assessment of existing clinical and histopathological data
|
|
Correlation Between Periostin Immunohistochemical Expression and Hospitalization History
Aikaikkuna: Baseline (retrospective assessment of existing clinical and histopathological data)
|
Correlation between periostin immunohistochemical expression measured using a semiquantitative 0-3 staining score in skin biopsy specimens and hospitalization history (yes/no) in patients with bullous pemphigoid.
|
Baseline (retrospective assessment of existing clinical and histopathological data)
|
|
Correlation Between Eosinophilic Cationic Protein Expression and Disease Relapse Frequency
Aikaikkuna: Baseline (retrospective assessment of existing clinical and histopathological data)
|
Correlation between eosinophilic cationic protein (ECP) immunohistochemical expression measured using a semiquantitative 0-3 staining score in skin biopsy specimens and disease relapse frequency (number of relapses) in patients with bullous pemphigoid.
|
Baseline (retrospective assessment of existing clinical and histopathological data)
|
|
Correlation Between Eosinophilic Cationic Protein Immunohistochemical Expression and Hospitalization History
Aikaikkuna: Baseline (retrospective assessment of existing clinical and histopathological data)
|
Correlation between eosinophilic cationic protein (ECP) immunohistochemical expression measured using a semiquantitative 0-3 staining score in skin biopsy specimens and hospitalization history (yes/no) in patients with bullous pemphigoid.
|
Baseline (retrospective assessment of existing clinical and histopathological data)
|
|
Correlation Between BPDAI Score and Eosinophilic Cationic Protein Expression
Aikaikkuna: Baseline (retrospective assessment of existing clinical, laboratory, and histopathological data)
|
Correlation between BPDAI disease activity score and tissue eosinophilic cationic protein (ECP) expression assessed by immunohistochemistry using a semiquantitative 0-3 staining score in skin biopsy specimens from patients with bullous pemphigoid.
|
Baseline (retrospective assessment of existing clinical, laboratory, and histopathological data)
|
Yhteistyökumppanit ja tutkijat
Tutkijat
- Opintojen puheenjohtaja: Ayse Esra Koku Aksu, Prof.Dr., University of Health Sciences, Istanbul Training and Research Hospital
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- SBU-IEAH-KAEK-20262404-26
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Rakkula pemfigoidi (BP)
-
Chengdu Kangnuoxing Biopharma,Inc.Ei vielä rekrytointiaStapokibart -injektion tutkimus koehenkilöillä, joilla on kohtalainen tai vakava bullous pemphigoidiRakkula pemfigoidi (BP)Kiina
-
University Hospital, RouenValmis
-
AKARI TherapeuticsValmisRakkula pemfigoidi (BP)Saksa, Alankomaat
-
Centre Hospitalier Universitaire de NiceValmis
-
University Hospital, LimogesValmisAutoimmuuninen rakkuladermatoosiRanska
-
University of Alabama at BirminghamGenentech, Inc.; BiogenValmisSilmän hampaiden pemfigoidiYhdysvallat
-
Centre Hospitalier Régional Metz-ThionvilleRekrytointiLäpäisevä keratoplastia | Bullous pseudofakainen keratopatiaRanska
-
Seoul National University HospitalMinistry of Health & Welfare, KoreaSaatavillaLimbaalisten kantasolujen puutos | Silmän hampaiden pemfigoidi | Stevens-Johnsonin syndrooma | Kemiallinen palovammaKorean tasavalta
-
Bioverativ, a Sanofi companyAssign Data Management and Biostatistics GmbH; Quest Diagnostics-Nichols... ja muut yhteistyökumppanitValmisLoppuvaiheen munuaistauti (ESRD) | Kylmä agglutiniinitauti (CAD) | Rakkula pemfigoidi (BP) | Lämmin autoimmuuninen hemolyyttinen anemia (WAIHA)Itävalta
-
Centre hospitalier de l'Université de Montréal...Implandata Ophthalmic Products GmbHPeruutettuGlaukooma | Sarveiskalvon sameus | Keratiitti, herpeettinen | Sarveiskalvon sairaus | Sarveiskalvon vammat | Sokeus, hankittu | Silmän hampaiden pemfigoidi